Results 161 to 170 of about 15,201 (184)

Clustering Analysis of Multiple Omics Data Types Identifies Cancer Patients With Consistent Survival Outcomes. [PDF]

Cancer Inform
Lin S, Qiu P.
europepmc   +1 more source

p53 and PD-1/PD-L1 expression contribute to disease progression and are correlated to immune infiltrates in urothelial carcinoma. [PDF]

Sci Rep
Zuo M, Liao Y, He P, Zhu Y, Huang T, Tang J, Fan L, Li X, Zhang N.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Chromium (VI) promotes EMT by regulating FLNA in BLCA

Environmental Toxicology, 2021
AbstractHexavalent chromium (Cr (VI)), which is a recognized human carcinogen, is widely used in industrial production of raw materials. Evidence verifies that environmental contaminants in the urine can induce malignant transformation in the urinary bladder tract, and our data indicate that Cr (VI) could promote the proliferation and migration and ...
Fei Sheng, Ke‐Xin Chen, Jian Liu, Jing‐Xian Li, Ge‐Hong Liang, Yong Xu, E Du, Zhi‐Hong Zhang   +7 more
openaire   +2 more sources

B lymphocyte/carcinoma antigen (BLCa): Functional study in B cells

Immunology & Cell Biology, 1988
SummaryBLCa is an antigen expressed on the surface of B lymphocytes and certain carcinomas. In this study we have demonstrated that BLCa is distinct from known B cell antigens classified by ‘clusters of differentiation’ (CD). In particular, the monoclonal antibody MA6, which identifies BLCa, can be distinguished from antibodies of the CDw40 group ...
H, Zola, S, Barclay, V, Furness, P J, Macardle, S H, Neoh, J, Bradley   +5 more
openaire   +2 more sources

The comprehensive and systematic identification of BLCA-specific SF-regulated, survival-related AS events

Gene, 2022
Bladder urothelial carcinoma (BLCA) is a complex disease with high morbidity and mortality. Changes in alternative splicing (AS) and splicing factor (SF) can affect gene expression, thus playing an essential role in tumorigenesis. This study downloaded 412 patients' clinical information and 433 samples of transcriptome profiling data from TCGA.
Zhe Liu, Xudong Liu, Fang Liu, Hui Zhao, Yu Zhang, Yafan Wang, Ying Ma, Fuzhou Wang, Weitong Zhang, Olutomilayo Olayemi Petinrin, Zhongyu Yao, Jingbo Liang, Qian He, Dayun Feng, Lei Wang, Ka-Chun Wong   +15 more
openaire   +2 more sources

A SHARED ANTIGENIC DETERMINANT BETWEEN HUMAN B LYMPHOCYTES AND CARCINOMAS (BLCa)

International Journal of Cancer, 1985
We have raised a murine 1gM monoclonal antibody (MA6) against immunoprecipitate obtained by reacting the serum of an NPC patient with extract of the Burkitt lymphoma cell line, Raji. It reacts against an antigen (BLCa) which is broadly represented on human B lymphoid tissues and cell lines but is different from the functional B‐cell markers such as ...
K H, Chan, T C, Yip, W L, Ng, M H, Ng
openaire   +2 more sources

CLINICAL USEFULNESS OF THE NOVEL MARKER BLCA-4 FOR THE DETECTION OF BLADDER CANCER

Journal of Urology, 2000
Previous studies at our laboratory identified 6 bladder cancer specific nuclear matrix proteins termed BLCA-1 to 6. We recently developed an immunoassay that detects the bladder cancer specific nuclear matrix protein BLCA-4. We analyzed urine samples from patients with bladder cancer, those with spinal cord injury and normal volunteers to determine the
B R, Konety, T S, Nguyen, G, Brenes, A, Sholder, N, Lewis, S, Bastacky, D M, Potter, R H, Getzenberg   +7 more
openaire   +2 more sources

USE OF THE NOVEL MARKER BLCA-1 FOR THE DETECTION OF BLADDER CANCER

Journal of Urology, 2005
Bladder cancer specific nuclear structural alterations have been identified. We examined the expression pattern of one of these proteins, BLCA-1, in tissue and urine samples from individuals with bladder cancer as well as in samples from normal controls.BLCA-1 sequence data were used to produce antibodies to this protein, which were used in immunoblot ...
Julie M, Myers-Irvin, Doug, Landsittel, Robert H, Getzenberg   +2 more
openaire   +2 more sources

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer

Cancer Immunology, Immunotherapy, 2004
Monoclonal antibodies (MAbs) can be used to detect, image and treat cancers. This study aimed to characterise the binding of BLCA-38 MAbs to human prostate cancer cell lines, human prostate cancer biopsy samples and normal tissues to enable future targeted studies.BLCA-38 antigen expression on cancer lines was determined by flow cytometry; that on ...
P J, Russell, K T, Ow, P N, Tam, J, Juarez, E A, Kingsley, C F, Qu, Y, Li, P J, Cozzi, R, Martiniello-Wilks   +8 more
openaire   +2 more sources

An Enhanced-BLCA for Assessing Performance of Company's Growth

2019 7th International Conference on Cyber and IT Service Management (CITSM), 2019
This paper purposes an improved algorithm of the butterfly lifecycle for calculating the performance of the company's growth. Three types of change for the better are regarding mathematical model, conception in calculating the growth performance parameters, and also data operated practically for testing the proposed algorithm.
openaire   +1 more source